Resolute Onyx DES for coronary artery disease

Resolute Onyx™ is a drug-eluting stent (DES) that's different by design, optimised for complex PCI, and proven safe and effective in real-world, high bleeding risk patients on 1-month dual antiplatelet therapy (DAPT).1

Download Brochure
Resolute Onyx stent product image on white background

Overview

Resolute Onyx DES is different by design to address your DES needs and a wide range of patient anatomies. It features:

  • Best-in-class deliverability2
  • Enhanced visibility with thinner struts2
  • Smooth side branch access2
  • Fast healing3
  • The broadest diameter range

Product Features

Best-in-class deliverability

Single-wire design

Resolute Onyx DES is made from a single wire, which gives it a fluid range of motion and provides the flexibility needed for best-in-class deliverability.2

Sinusoid formed wire detail on the Resolute Onyx DES

Sinusoid-formed wire

Close-up depiction of Resolute Onyx helical wrap

Helical wrap

Resolute Onyx laser-fused product

Laser-fused

Competitive comparison

Resolute Onyx DES is more deliverable than laser-cut SYNERGY™* XD and XIENCE Skypoint™*, which are stiffer.

Deliverability comparison — 3.0 mm DES2

(Lower is better)

Orange and gray bar chart comparing deliverability of Resolute Onyx to Synergy XD and Xience Skypoint
Review the Data

The Only DES Designed from a Single Wire‡

Proven components for optimal healing

Watch a short video to learn more about the BioLinx™ polymer.

  • Single-wire design provides a fluid range of motion and the conformability needed for superior strut apposition.2
  • BioLinx biocompatible polymer provides superior thromboresistance.4
  • When combined, fast healing occurs as evidenced by nearly 90% strut coverage at 30 days,3 providing the foundation for the Onyx ONE Global Trial.
  • The Onyx ONE Global Trial analysed real-world, high bleeding risk patients on 1-month DAPT treated with a Resolute Onyx DES or a BioFreedom™* DCS.
  • Results showed Resolute Onyx DES was safe and effective,1 providing the option to shorten DAPT in patients who are at high bleeding risk.
  • Based on these results, Resolute Onyx DES was the first DES CE-indicated for HBR patients on 1-month DAPT.
See the Onyx ONE Data

Enhanced visibility with thinner struts

Platinum-iridium core within Resolute Onyx DES increases visibility for accurate stent placement without compromising strut thickness.2

Average visibility comparison2

(Higher is better)

Orange and gray bar chart comparing visibility of Resolute Onyx drug-eluting stent to Synergy, Xience, and Orsiro DES.
  1. Cobalt alloy shell
  2. Platinum iridium core
Close-up of the Resolute Onyx cobalt alloy shell and platinum-iridium core

Resolute Onyx cobalt alloy shell and platinum-iridum core

Smooth side branch access

Resolute Onyx DES has round struts to create a smooth passage when accessing the side branch and lower the propensity to catch during bifurcation procedures.2

Strut comparison

Rounded strut cross-section

  1. Resolute Onyx DES

Illustration of Resolute Onyx DES rounded struts

Square strut cross-section

  1. SYNERGY™* DES
  2. XIENCE™* DES
Illustration of square struts used by competitive coronary stents

Broadest diameter range

  • Complex PCI requires a broad DES size matrix to match a wide range of patient anatomies.
  • Resolute Onyx is the only DES with diameters ranging from 2.0 mm to 5.0 mm to treat a broad range of coronary vessel sizes.

Diameter (mm)

          

Stent Length (mm)

Maximum Expansion
Capabilities (MSID†) (mm) 

2.00

8

12

15

18

22

26

30

—

—

3.50‡

2.25

8

12

15

18

22

26

30

34

38

3.50‡

2.50

8

12

15

18

22

26

30

34

38

3.50‡

2.75

8

12

15

18

22

26

30

34

38

4.00‡

3.00

8

12

15

18

22

26

30

34

38

4.00‡

3.50

8

12

15

18

22

26

30

34

38

5.00‡

4.00

8

12

15

18

22

26

30

34

38

5.00‡

4.50

—

12

15

18

22

26

30

—

—

6.00‡

5.00

—

12

15

18

22

26

30

—

—

6.00‡

PRODUCT DETAILS

 Stent Diameter (mm) Stent Length (mm)
8 12 15 18 22 26 30 34 38
2.00 RONYX20008X RONYX20012X RONYX20015X RONYX20018X RONYX20022X RONYX20026X RONYX20030X N/A N/A
2.25 RONYX22508X RONYX22512X RONYX22515X RONYX22518X RONYX22522X RONYX22526X RONYX22530X RONYX22534X RONYX22538X
2.50 RONYX25008X RONYX25012X RONYX25015X RONYX25018X RONYX25022X RONYX25026X RONYX25030X RONYX25034X RONYX25038X
2.75 RONYX27508X RONYX27512X RONYX27515X RONYX27518X RONYX27522X RONYX27526X RONYX27530X RONYX27534X RONYX27538X
3.00 RONYX30008X RONYX30012X RONYX30015X RONYX30018X RONYX30022X RONYX30026X RONYX30030X RONYX30034X RONYX30038X
3.50 RONYX35008X RONYX35012X RONYX35015X RONYX35015X RONYX35022X RONYX35026X RONYX35030X RONYX35034X RONYX35038X
4.00 RONYX40008X RONYX40012X RONYX40015X RONYX40018X RONYX40022X RONYX40026X RONYX40030X RONYX40034X RONYX40038X
4.50 N/A RONYX45012X RONYX45015X RONYX45018X RONYX45022X RONYX45026X RONYX45030X N/A N/A
5.00  N/A RONYX50012X RONYX50015X RONYX50018X RONYX50022X RONYX50026X RONYX50030X N/A N/A

Maximum expansion capabilities

For reference only in markets where the Resolute Onyx coronary stent and the 0.25 mm expansion have been approved.

Additional Resources

Onyx ONE Global Trial

First randomised, 1-month DAPT trial comparing a DES to a DES in ~2000 high bleeding risk patients on 1-month DAPT.

Review the Data

Resolute Onyx DES is optimised for complex PCI

Resolute Onyx DES design exclusives make it ideal for complex cases.

See How

Bifurcation education

View five techniques that highlight Resolute Onyx DES through endoscopic imaging captured inside an isolated and reanimated beating porcine heart.

Visit and Bookmark

The Resolute Onyx DES zotarolimus drug effectively inhibits neointimal growth while the exclusive, highly biocompatible BioLinx™ polymer contributes to minimal inflammation, low thrombotic risk,5 as well as rapid, complete, and functional endothelial healing.§4

pdf Onyx One Results Brochure (.pdf)

This brochure presents clinical evidence about Onyx One.

307KB

This brochure presents clinical evidence about Onyx One.

request more information

Contact us
*

As per April 2021.

†

Medtronic and Medtronic logo are trademarks of Medtronic.  Third-party trademarks ("™†") belong to their respective owners.  All other brands are trademarks of a Medtronic entity.

‡

Including Resolute Integrity™ DES, part of the Medtronic DES portfolio.

§

In porcine models.

References

1

Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.

2

Based on bench test data on file at Medtronic. May not be indicative of clinical performance.

3

Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.

4

Jinnouchi H, Sato Y, Cheng Q, et al. Int J Cardiol. March 2021;327:52-57.